Vanda Pharmaceuticals (VNDA) Competitors

$6.39 -0.04 (-0.62%)

Closing price 04:00 PM Eastern

Extended Trading

$6.46 +0.08 (+1.17%)

As of 06:02 PM Eastern

VNDA vs. ZBIO, MNKD, LXRX, GERN, and OPK

Should you buy Vanda Pharmaceuticals stock or one of its competitors? MarketBeat compares Vanda Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Vanda Pharmaceuticals include Zenas BioPharma (ZBIO), MannKind (MNKD), Lexicon Pharmaceuticals (LXRX), Geron (GERN), and OPKO Health (OPK). These companies are all part of the "biotechnology" industry.

How does Vanda Pharmaceuticals compare to Zenas BioPharma?

Vanda Pharmaceuticals (NASDAQ:VNDA) and Zenas BioPharma (NASDAQ:ZBIO) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, institutional ownership, valuation, dividends, profitability and media sentiment.

Vanda Pharmaceuticals has a beta of 0.65, meaning that its share price is 35% less volatile than the broader market. Comparatively, Zenas BioPharma has a beta of -0.61, meaning that its share price is 161% less volatile than the broader market.

88.1% of Vanda Pharmaceuticals shares are held by institutional investors. 10.0% of Vanda Pharmaceuticals shares are held by company insiders. Comparatively, 22.0% of Zenas BioPharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Zenas BioPharma has a net margin of 0.00% compared to Vanda Pharmaceuticals' net margin of -109.99%. Vanda Pharmaceuticals' return on equity of -32.26% beat Zenas BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vanda Pharmaceuticals	-109.99%	-32.26%	-23.43%
Zenas BioPharma	N/A	-85.64%	-61.86%

Vanda Pharmaceuticals has higher revenue and earnings than Zenas BioPharma. Zenas BioPharma is trading at a lower price-to-earnings ratio than Vanda Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vanda Pharmaceuticals	$216.10M	1.78	-$220.47M	-$4.05	N/A
Zenas BioPharma	$10M	108.43	-$377.74M	-$7.81	N/A

In the previous week, Vanda Pharmaceuticals had 11 more articles in the media than Zenas BioPharma. MarketBeat recorded 18 mentions for Vanda Pharmaceuticals and 7 mentions for Zenas BioPharma. Zenas BioPharma's average media sentiment score of 1.05 beat Vanda Pharmaceuticals' score of 0.43 indicating that Zenas BioPharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vanda Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Zenas BioPharma	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Vanda Pharmaceuticals currently has a consensus target price of $14.30, suggesting a potential upside of 123.79%. Zenas BioPharma has a consensus target price of $44.29, suggesting a potential upside of 134.32%. Given Zenas BioPharma's higher probable upside, analysts plainly believe Zenas BioPharma is more favorable than Vanda Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vanda Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Zenas BioPharma	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.44

Summary

Vanda Pharmaceuticals beats Zenas BioPharma on 10 of the 16 factors compared between the two stocks.

How does Vanda Pharmaceuticals compare to MannKind?

Vanda Pharmaceuticals (NASDAQ:VNDA) and MannKind (NASDAQ:MNKD) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, institutional ownership, valuation, dividends, profitability and media sentiment.

Vanda Pharmaceuticals has a beta of 0.65, meaning that its share price is 35% less volatile than the broader market. Comparatively, MannKind has a beta of 1.04, meaning that its share price is 4% more volatile than the broader market.

Vanda Pharmaceuticals currently has a consensus target price of $14.30, suggesting a potential upside of 123.79%. MannKind has a consensus target price of $8.84, suggesting a potential upside of 174.65%. Given MannKind's stronger consensus rating and higher probable upside, analysts plainly believe MannKind is more favorable than Vanda Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vanda Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
MannKind	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60

MannKind has higher revenue and earnings than Vanda Pharmaceuticals. MannKind is trading at a lower price-to-earnings ratio than Vanda Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vanda Pharmaceuticals	$216.10M	1.78	-$220.47M	-$4.05	N/A
MannKind	$360.78M	2.76	$5.86M	-$0.07	N/A

MannKind has a net margin of -6.63% compared to Vanda Pharmaceuticals' net margin of -109.99%. MannKind's return on equity of -11.21% beat Vanda Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vanda Pharmaceuticals	-109.99%	-32.26%	-23.43%
MannKind	-6.63%	-11.21%	-3.92%

88.1% of Vanda Pharmaceuticals shares are held by institutional investors. Comparatively, 49.5% of MannKind shares are held by institutional investors. 10.0% of Vanda Pharmaceuticals shares are held by company insiders. Comparatively, 2.6% of MannKind shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Vanda Pharmaceuticals had 7 more articles in the media than MannKind. MarketBeat recorded 18 mentions for Vanda Pharmaceuticals and 11 mentions for MannKind. Vanda Pharmaceuticals' average media sentiment score of 0.43 beat MannKind's score of 0.29 indicating that Vanda Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vanda Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
MannKind	3 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

MannKind beats Vanda Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Vanda Pharmaceuticals compare to Lexicon Pharmaceuticals?

Lexicon Pharmaceuticals (NASDAQ:LXRX) and Vanda Pharmaceuticals (NASDAQ:VNDA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, dividends, media sentiment, valuation and risk.

Lexicon Pharmaceuticals has a beta of 0.97, indicating that its stock price is 3% less volatile than the broader market. Comparatively, Vanda Pharmaceuticals has a beta of 0.65, indicating that its stock price is 35% less volatile than the broader market.

Lexicon Pharmaceuticals has higher earnings, but lower revenue than Vanda Pharmaceuticals. Lexicon Pharmaceuticals is trading at a lower price-to-earnings ratio than Vanda Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lexicon Pharmaceuticals	$49.80M	20.78	-$50.34M	-$0.07	N/A
Vanda Pharmaceuticals	$216.10M	1.78	-$220.47M	-$4.05	N/A

Lexicon Pharmaceuticals presently has a consensus target price of $4.55, indicating a potential upside of 95.28%. Vanda Pharmaceuticals has a consensus target price of $14.30, indicating a potential upside of 123.79%. Given Vanda Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Vanda Pharmaceuticals is more favorable than Lexicon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexicon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Vanda Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Lexicon Pharmaceuticals has a net margin of -37.46% compared to Vanda Pharmaceuticals' net margin of -109.99%. Lexicon Pharmaceuticals' return on equity of -18.64% beat Vanda Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lexicon Pharmaceuticals	-37.46%	-18.64%	-11.79%
Vanda Pharmaceuticals	-109.99%	-32.26%	-23.43%

In the previous week, Lexicon Pharmaceuticals had 1 more articles in the media than Vanda Pharmaceuticals. MarketBeat recorded 19 mentions for Lexicon Pharmaceuticals and 18 mentions for Vanda Pharmaceuticals. Lexicon Pharmaceuticals' average media sentiment score of 0.63 beat Vanda Pharmaceuticals' score of 0.43 indicating that Lexicon Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lexicon Pharmaceuticals	2 Very Positive mention(s)	4 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Vanda Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

74.7% of Lexicon Pharmaceuticals shares are held by institutional investors. Comparatively, 88.1% of Vanda Pharmaceuticals shares are held by institutional investors. 14.0% of Lexicon Pharmaceuticals shares are held by company insiders. Comparatively, 10.0% of Vanda Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Lexicon Pharmaceuticals beats Vanda Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Vanda Pharmaceuticals compare to Geron?

Geron (NASDAQ:GERN) and Vanda Pharmaceuticals (NASDAQ:VNDA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk, media sentiment and dividends.

Geron has a beta of 0.68, indicating that its share price is 32% less volatile than the broader market. Comparatively, Vanda Pharmaceuticals has a beta of 0.65, indicating that its share price is 35% less volatile than the broader market.

Geron has higher earnings, but lower revenue than Vanda Pharmaceuticals. Geron is trading at a lower price-to-earnings ratio than Vanda Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Geron	$183.88M	4.88	-$83.50M	-$0.11	N/A
Vanda Pharmaceuticals	$216.10M	1.78	-$220.47M	-$4.05	N/A

Geron presently has a consensus target price of $2.50, indicating a potential upside of 78.57%. Vanda Pharmaceuticals has a consensus target price of $14.30, indicating a potential upside of 123.79%. Given Vanda Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Vanda Pharmaceuticals is more favorable than Geron.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Geron	2 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
Vanda Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Geron has a net margin of -35.48% compared to Vanda Pharmaceuticals' net margin of -109.99%. Geron's return on equity of -23.31% beat Vanda Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Geron	-35.48%	-23.31%	-10.08%
Vanda Pharmaceuticals	-109.99%	-32.26%	-23.43%

In the previous week, Vanda Pharmaceuticals had 2 more articles in the media than Geron. MarketBeat recorded 18 mentions for Vanda Pharmaceuticals and 16 mentions for Geron. Geron's average media sentiment score of 0.75 beat Vanda Pharmaceuticals' score of 0.43 indicating that Geron is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Geron	3 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vanda Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

73.7% of Geron shares are owned by institutional investors. Comparatively, 88.1% of Vanda Pharmaceuticals shares are owned by institutional investors. 1.7% of Geron shares are owned by insiders. Comparatively, 10.0% of Vanda Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Geron and Vanda Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does Vanda Pharmaceuticals compare to OPKO Health?

OPKO Health (NASDAQ:OPK) and Vanda Pharmaceuticals (NASDAQ:VNDA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk, media sentiment and dividends.

Vanda Pharmaceuticals has lower revenue, but higher earnings than OPKO Health. OPKO Health is trading at a lower price-to-earnings ratio than Vanda Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OPKO Health	$581.12M	1.43	-$225.68M	-$0.27	N/A
Vanda Pharmaceuticals	$216.10M	1.78	-$220.47M	-$4.05	N/A

OPKO Health has a beta of 1.42, indicating that its share price is 42% more volatile than the broader market. Comparatively, Vanda Pharmaceuticals has a beta of 0.65, indicating that its share price is 35% less volatile than the broader market.

64.6% of OPKO Health shares are owned by institutional investors. Comparatively, 88.1% of Vanda Pharmaceuticals shares are owned by institutional investors. 49.7% of OPKO Health shares are owned by insiders. Comparatively, 10.0% of Vanda Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

OPKO Health has a net margin of -36.63% compared to Vanda Pharmaceuticals' net margin of -109.99%. OPKO Health's return on equity of -16.78% beat Vanda Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OPKO Health	-36.63%	-16.78%	-10.98%
Vanda Pharmaceuticals	-109.99%	-32.26%	-23.43%

OPKO Health presently has a consensus target price of $1.55, indicating a potential upside of 40.91%. Vanda Pharmaceuticals has a consensus target price of $14.30, indicating a potential upside of 123.79%. Given Vanda Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Vanda Pharmaceuticals is more favorable than OPKO Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OPKO Health	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.17
Vanda Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Vanda Pharmaceuticals had 11 more articles in the media than OPKO Health. MarketBeat recorded 18 mentions for Vanda Pharmaceuticals and 7 mentions for OPKO Health. OPKO Health's average media sentiment score of 0.61 beat Vanda Pharmaceuticals' score of 0.43 indicating that OPKO Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OPKO Health	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vanda Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

OPKO Health beats Vanda Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

Get Vanda Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VNDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VNDA vs. The Competition

Export

Metric	Vanda Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$384.23M	$3.40B	$6.29B	$12.46B
Dividend Yield	N/A	2.31%	2.79%	5.30%
P/E Ratio	-1.58	18.98	20.89	25.59
Price / Sales	1.78	176.16	522.17	62.83
Price / Cash	N/A	122.51	42.94	55.34
Price / Book	1.37	6.74	9.86	6.70
Net Income	-$220.47M	$24.11M	$3.55B	$333.77M
7 Day Performance	N/A	0.06%	-0.32%	0.45%
1 Month Performance	-12.70%	0.81%	1.33%	4.06%
1 Year Performance	63.01%	78.08%	41.10%	36.24%

Vanda Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VNDA Vanda Pharmaceuticals	2.834 of 5 stars	$6.39 -0.6%	$14.30 +123.8%	+61.6%	$384.23M	$216.10M	N/A	290	Trending News Analyst Forecast Analyst Revision
ZBIO Zenas BioPharma	3.3688 of 5 stars	$20.40 +3.9%	$44.14 +116.4%	+119.3%	$1.17B	$10M	N/A	N/A	News Coverage Earnings Report Analyst Forecast
MNKD MannKind	3.7163 of 5 stars	$3.36 -4.5%	$8.84 +163.2%	-32.0%	$1.04B	$360.78M	N/A	400
LXRX Lexicon Pharmaceuticals	2.616 of 5 stars	$2.31 +15.5%	$4.55 +97.0%	+287.3%	$1.03B	$49.80M	N/A	140	Earnings Report Analyst Forecast Analyst Revision High Trading Volume
GERN Geron	2.7917 of 5 stars	$1.39 flat	$2.50 +79.9%	+17.5%	$891.71M	$183.88M	N/A	70

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VNDA) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vanda Pharmaceuticals (VNDA) Competitors

VNDA vs. ZBIO, MNKD, LXRX, GERN, and OPK

How does Vanda Pharmaceuticals compare to Zenas BioPharma?

Summary

How does Vanda Pharmaceuticals compare to MannKind?

Summary

How does Vanda Pharmaceuticals compare to Lexicon Pharmaceuticals?

Summary

How does Vanda Pharmaceuticals compare to Geron?

Summary

How does Vanda Pharmaceuticals compare to OPKO Health?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VNDA vs. The Competition

Vanda Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Vanda Pharmaceuticals (VNDA) Competitors

VNDA vs. ZBIO, MNKD, LXRX, GERN, and OPK

How does Vanda Pharmaceuticals compare to Zenas BioPharma?

Which has more risk & volatility, VNDA or ZBIO?

Do insiders and institutionals believe in VNDA or ZBIO?

Is VNDA or ZBIO more profitable?

Which has preferable valuation & earnings, VNDA or ZBIO?

Does the media prefer VNDA or ZBIO?

Do analysts recommend VNDA or ZBIO?

Summary

How does Vanda Pharmaceuticals compare to MannKind?

Which has more risk & volatility, VNDA or MNKD?

Do analysts recommend VNDA or MNKD?

Which has preferable valuation & earnings, VNDA or MNKD?

Is VNDA or MNKD more profitable?

Do insiders and institutionals believe in VNDA or MNKD?

Does the media prefer VNDA or MNKD?

Summary

How does Vanda Pharmaceuticals compare to Lexicon Pharmaceuticals?

Which has more risk and volatility, LXRX or VNDA?

Which has better valuation and earnings, LXRX or VNDA?

Do analysts recommend LXRX or VNDA?

Is LXRX or VNDA more profitable?

Does the media favor LXRX or VNDA?

Do institutionals and insiders believe in LXRX or VNDA?

Summary

How does Vanda Pharmaceuticals compare to Geron?

Which has more volatility & risk, GERN or VNDA?

Which has preferable earnings and valuation, GERN or VNDA?

Do analysts recommend GERN or VNDA?

Is GERN or VNDA more profitable?

Does the media favor GERN or VNDA?

Do insiders & institutionals believe in GERN or VNDA?

Summary

How does Vanda Pharmaceuticals compare to OPKO Health?

Which has preferable earnings and valuation, OPK or VNDA?

Which has more volatility & risk, OPK or VNDA?

Do insiders & institutionals believe in OPK or VNDA?

Is OPK or VNDA more profitable?

Do analysts recommend OPK or VNDA?

Does the media favor OPK or VNDA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VNDA vs. The Competition

Vanda Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools